Technical Analysis for ACOR - Acorda Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.66 | -24.86% | -0.22 |
Earnings due: May 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -24.86% | |
| Calm After Storm | Range Contraction | -24.86% |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Acorda Therapeutics, Inc. Description
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Antibodies Autoimmune Disease Clinical Trial Chloride Heart Failure Stroke Central Nervous System Disorders Multiple Sclerosis Nervous System Disorders Potassium DSL Seizure Spinal Cord Treatment Of Heart Failure Nasal Spray Spasticity Spinal Cord Injury Zanaflex
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.196 |
| 52 Week Low | 0.6116 |
| Average Volume | 159,356 |
| 200-Day Moving Average | 13.11 |
| 50-Day Moving Average | 11.80 |
| 20-Day Moving Average | 8.15 |
| 10-Day Moving Average | 3.80 |
| Average True Range | 1.06 |
| RSI (14) | 16.67 |
| ADX | 39.38 |
| +DI | 10.11 |
| -DI | 62.60 |
| Chandelier Exit (Long, 3 ATRs) | 10.92 |
| Chandelier Exit (Short, 3 ATRs) | 3.80 |
| Upper Bollinger Bands | 19.22 |
| Lower Bollinger Band | -2.92 |
| Percent B (%b) | 0.16 |
| BandWidth | 271.55 |
| MACD Line | -3.44 |
| MACD Signal Line | -2.55 |
| MACD Histogram | -0.8974 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.02 | ||||
| Resistance 3 (R3) | 1.04 | 0.95 | 0.96 | ||
| Resistance 2 (R2) | 0.95 | 0.85 | 0.93 | 0.94 | |
| Resistance 1 (R1) | 0.80 | 0.80 | 0.76 | 0.78 | 0.92 |
| Pivot Point | 0.71 | 0.71 | 0.68 | 0.70 | 0.71 |
| Support 1 (S1) | 0.57 | 0.62 | 0.52 | 0.54 | 0.40 |
| Support 2 (S2) | 0.47 | 0.56 | 0.46 | 0.38 | |
| Support 3 (S3) | 0.33 | 0.47 | 0.36 | ||
| Support 4 (S4) | 0.30 |
